Evogene Ltd. EVGN
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -35.02% | -79.65% | 128.16% | -44.08% | 708.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.02% | -79.65% | 128.16% | -44.08% | 708.37% |
| Cost of Revenue | 51.47% | 230.06% | -59.52% | 389.35% | 325.83% |
| Gross Profit | -64.57% | -331.49% | 117.83% | -78.71% | 841.04% |
| SG&A Expenses | -3.86% | -26.81% | -13.74% | -40.55% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.05% | 5.41% | -36.97% | -28.31% | 5.12% |
| Operating Income | -28.75% | -43.28% | 69.36% | 9.78% | 41.06% |
| Income Before Tax | 42.18% | -639.19% | 57.97% | 50.51% | 46.03% |
| Income Tax Expenses | -- | -100.00% | -- | -- | -200.00% |
| Earnings from Continuing Operations | 42.39% | -643.03% | 57.96% | 50.51% | 46.14% |
| Earnings from Discontinued Operations | 79.70% | 98.38% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.46% | -89.58% | -61.31% | 2,333.33% | -120.36% |
| Net Income | 60.39% | -1,343.33% | 17.64% | 33.03% | 39.12% |
| EBIT | -28.75% | -43.28% | 69.36% | 9.78% | 41.06% |
| EBITDA | -37.20% | -23.05% | 72.75% | -0.41% | 45.41% |
| EPS Basic | 76.81% | -316.57% | 41.30% | 49.93% | 48.71% |
| Normalized Basic EPS | -- | -- | -- | -- | 44.48% |
| EPS Diluted | 76.81% | -316.57% | 41.30% | 49.93% | 48.71% |
| Normalized Diluted EPS | -- | -- | -- | -- | 44.48% |
| Average Basic Shares Outstanding | 73.99% | 53.03% | 37.84% | 33.74% | 18.70% |
| Average Diluted Shares Outstanding | 73.99% | 53.03% | 37.84% | 33.74% | 18.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |